The effect of the amelogenin fraction of enamel matrix proteins on fibroblast-mediated collagen matrix reorganization.
Enamel matrix proteins (EMP), extracted from developing porcine teeth, promote not only periodontal regeneration but also cutaneous wound healing presumably via the amelogenin fraction. Because it is unclear whether the effect of EMP can be ascribed to amelogenins, we compared EMP with recombinant amelogenin in the relaxed dermal equivalent (DE) in vitro model for early wound contraction. EMP and recombinant porcine amelogenin (rP172) at 1 mg/ml were incorporated into DEs composed of human dermal fibroblasts and a type I collagen matrix. The area reduction, as a measure of contraction, as well as fibroblast numbers and TGF-beta1 levels, were quantified over 7 days in culture in the presence of 10% foetal bovine serum. Both EMP and recombinant amelogenin increased contraction (p < 0.005) and fibroblast numbers (p < 0.005) compared with controls (acetic acid vehicle and 1mg/ml porcine serum albumin) and the positive control TGF-beta1 added at 10 ng/ml. Increased contraction with EMP and recombinant amelogenin was most pronounced after the first day of incubation and was associated with elevated (p < 0.005) TGF-beta1 levels in conditioned medium. In conclusion, the amelogenin component of EMP augmented fibroblast-driven collagen matrix remodelling, at least partially, by increasing the endogenous production of TGF-beta1. These effects of EMP/amelogenin may be beneficial for cutaneous wound healing.
Grayson
Rachel E
RE
Department of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
Yamakoshi
Y
Y
Wood
Edward J
EJ
Agren
Magnus S
MS
D000566:Amelogenesis / Q000187:drug effects / Q000502:physiology*; D053523:Amelogenin; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000502:physiology*; D003746:Dental Enamel Proteins / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005109:Extracellular Matrix / Q000187:drug effects / Q000502:physiology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D012867:Skin / Q000166:cytology / Q000187:drug effects; D012879:Skin Physiological Phenomena / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*; D053773:Transforming Growth Factor beta1
D053523:Amelogenin; D024042:Collagen Type I; D003746:Dental Enamel Proteins; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C109069:enamel matrix proteins